SOLID BIOSCIENCES INC (SLDB) Stock Price, Quote, News and Overview
NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD
SLDB Quote, Performance and Key Statistics
SOLID BIOSCIENCES INC
NASDAQ:SLDB (2/11/2025, 12:41:05 PM)
3.2
-0.24 (-6.98%)
The current stock price of SLDB is 3.2 USD. In the past month the price decreased by -6.52%. In the past year, price decreased by -65.67%.
SLDB Latest News and Analysis
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN,...
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three...
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company...
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia - - Dual...
SLDB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.87 | 337.47B | ||
| AMGN | AMGEN INC | 14.87 | 158.39B | ||
| GILD | GILEAD SCIENCES INC | 21.6 | 119.23B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1584.17 | 118.31B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.72 | 73.83B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.83B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.38B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 22.14B | ||
| BIIB | BIOGEN INC | 8.59 | 20.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.98B |
Related stock screener links
About SLDB
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 88 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The firm also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. The company also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139 US
CEO: Ilan Ganot
Employees: 88
Company Website: https://www.solidbio.com/
Investor Relations: https://investors.solidbio.com/
Phone: 16173374680
SLDB FAQ
What is the stock price of SLDB?
The current stock price of SLDB is 3.2 USD.
What is the symbol for SOLID BIOSCIENCES INC stock?
The exchange symbol of SOLID BIOSCIENCES INC is SLDB and it is listed on the Nasdaq exchange.
On which exchange is SLDB stock listed?
SLDB stock is listed on the Nasdaq exchange.
Is SLDB a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SLDB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SLDB.
Does SLDB stock pay dividends?
SLDB does not pay a dividend.
What is the Price/Earnings (PE) ratio of SLDB?
SLDB does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
What is the Short Interest ratio of SLDB stock?
The outstanding short interest for SLDB is 7.14% of its float.
SLDB Technical Analysis
SLDB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLDB. SLDB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLDB Financial Highlights
Over the last trailing twelve months SLDB reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS decreased by 54.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.26% | ||
| ROE | -46.93% | ||
| Debt/Equity | 0 |
SLDB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to SLDB. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 37.56% and a revenue growth -100% for SLDB